| Stock Name | MIRXES-B |
|---|---|
| Stock Code | 02629 |
| Company Full Name | MIRXES-B |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家總部位于新加坡的miRNA技術公司，致力于使疾病篩查診斷解決方案在亞洲關鍵市場（包括新加坡及中國）觸手可及。 |
| Listing Date | 2025-05-23 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省湖州市安吉縣遞鋪街道半島中路198號2幢1層26號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://mirxes.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
| Offering Mechanism | 18A生物科技 |
|---|---|
| Offer Price | HK$ 23.30 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2025-05-15 to 2025-05-20 |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 41.4% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 136,857,210 |
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 100 | HK$ 2,330 |
| 2 lots | 200 | HK$ 4,660 |
| 3 lots | 300 | HK$ 6,990 |
| 4 lots | 400 | HK$ 9,320 |
| 5 lots | 500 | HK$ 11,650 |
| 6 lots | 600 | HK$ 13,980 |
| 7 lots | 700 | HK$ 16,310 |
| 8 lots | 800 | HK$ 18,640 |
| 9 lots | 900 | HK$ 20,970 |
| 10 lots | 1,000 | HK$ 23,300 |
| 20 lots | 2,000 | HK$ 46,600 |
| 30 lots | 3,000 | HK$ 69,900 |
| 40 lots | 4,000 | HK$ 93,200 |
| 50 lots | 5,000 | HK$ 116,500 |
| 60 lots | 6,000 | HK$ 139,800 |
| 70 lots | 7,000 | HK$ 163,100 |
| 80 lots | 8,000 | HK$ 186,400 |
| 90 lots | 9,000 | HK$ 209,700 |
| 100 lots | 10,000 | HK$ 233,000 |
| 200 lots | 20,000 | HK$ 466,000 |
| 300 lots | 30,000 | HK$ 699,000 |
| 400 lots | 40,000 | HK$ 932,000 |
| 500 lots | 50,000 | HK$ 1,165,000 |
| 1,000 lots | 100,000 | HK$ 2,330,000 |
| 1,500 lots | 150,000 | HK$ 3,495,000 |
| 2,000 lots | 200,000 | HK$ 4,660,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,500 lots | 250,000 | HK$ 5,825,000 |
| 3,000 lots | 300,000 | HK$ 6,990,000 |
| 3,500 lots | 350,000 | HK$ 8,155,000 |
| 4,000 lots | 400,000 | HK$ 9,320,000 |
| 4,500 lots | 450,000 | HK$ 10,485,000 |
| 5,000 lots | 500,000 | HK$ 11,650,000 |
| 6,000 lots | 600,000 | HK$ 13,980,000 |
| 7,000 lots | 700,000 | HK$ 16,310,000 |
| 10,000 lots | 1,000,000 | HK$ 23,300,000 |
| 15,000 lots | 1,500,000 | HK$ 34,950,000 |
| 20,000 lots | 2,000,000 | HK$ 46,600,000 |
| 23,310 lots | 2,331,000 | HK$ 54,312,300 |
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 30.0 |
|---|---|
| First Day Open | HK$ 29.0 |
| First Day Change | 28.76% |
| First Day Volume | 9178740.0 |
| First Day Turnover | 274943000.0 |
| Use of Proceeds | 1、約449.3百萬港元或51%預計將主要用于公司核心產品GASTROClearTM的研發、監管備案以及生產及商業化； 2、約211.0百萬港元或24%將為正在進行及計劃進行的研發提供資金，以進一步開發公司的管線產品； 3、約132.1百萬港元或15%將用于加強并整合公司的「端到端」能力，以把握價值鏈上的巨大商業潛力； 4、約88.0百萬港元或10%將用作公司的營運資金及其他一般公司用途。 |
|---|
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Evergreen Gate Limited | 61,446,760 HKD | — | 5.66% | — | 6 months | 2025-11-23 |
| 2 | 北京浔瑞企业管理合伙企业(有限合伙) | 387,926,360 HKD | — | 35.71% | — | 6 months | 2025-11-23 |
| Chairman | 朱興奮 |
|---|---|
| Company Secretary | 蕭月秋,歐陽葦芝 |
| Major Shareholders & Holdings | Central Road Holdings Limited(18.31%),朱興奮(11.73%),SLW Gene Limited(6.75%),Accurate Gene Limited(6.46%),MSEA Ltd(5.49%) |
|---|
Market Sentiment
The IPO's oversubscription ratio of 25.51x indicates moderate retail enthusiasm, with the offer price of HK$23.30 likely set at an attractive level. The 0.0% hit rate and triggered reallocation point to extreme scarcity in retail allotments, typical of hot IPOs where single-lot allocations dominate. Market sentiment appears cautiously optimistic, driven by the biotech sector's speculative appeal. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
A clear tier anomaly is present: both 甲尾 (A-tail) at a HK$200,000 application and 乙头 (B-head) at HK$250,000 are expected to receive just 1 lot each, offering zero incremental benefit for the higher B-head commitment. This flat allocation structure makes the B-head tier exceptionally cost-inefficient relative to the A-tail, as the extra HK$50,000 yields no additional shares. Investors might rationally avoid the B-head unless seeking to avoid odd-lot complications, though broker fee differentials could slightly alter this calculus. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
Demographic data is absent for this IPO, with mainland and Hong Kong participation both reported at 0%, likely due to data collection lag or omissions. Without reliable breakdowns, trends in mainland capital inflow, gender splits, or regional concentration cannot be assessed. This limitation prevents any meaningful demographic pattern analysis for this offering. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
